Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to identify pain sources in chronic low back pain, has added Lanman Spinal Neurosurgery as a clinical site in its CLARITY trial. Based in Beverly Hills, this private practice is known for complex spinal procedures and high surgical volume, marking the first private practice site in the study. The addition reflects growing interest in integrating Aclarion's Nociscan platform into real-world clinical workflows beyond academic centers.
The CLARITY trial is a prospective, randomized, multi-center study evaluating Nociscan in 300 patients undergoing surgical treatment for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS at 12 months. Aclarion anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026.
Dr. Todd Lanman, founder of Lanman Spinal Neurosurgery, emphasized the importance of precise diagnosis: "We have made significant progress in moving beyond one-size-fits-all solutions for low back pain. Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot. This ability to match the right procedure to the right patient is what moves the field forward."
Ryan Bond, Chief Strategy Officer of Aclarion, noted that private practice spine surgeons treat the majority of chronic low back pain patients. "The inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice," he said. "Dr. Lanman is recognized for his commitment to innovation, and we are excited to partner with his team to generate high-quality evidence needed to advance Nociscan."
Chronic low back pain affects approximately 266 million people worldwide. Aclarion's Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It objectively quantifies chemical biomarkers associated with disc pain, and when all Nociscan-positive discs are treated, it demonstrates a 97% surgical success rate. For more information about the CLARITY trial, visit CLARITY Trial. To find a Nociscan center, view the site map here.
